Cytori Therapeutics' Big Upside - Analyst Blog
This is clearly an exciting time for
Cytori Therapeutics Inc. (
CYTX), as the company has begun to record product sales revenues from early-adopter Celution System placements in Europe and Asia. Additionally, sales of StemSource cell banking are also now beginning to ramp.
Ultimately, the clinical data will determine the pace at which the ramp continues in the next several years. We have been encouraged by the small clinical data seen so far using Cytori's technology. We think the company is in store to report a solid fourth quarter, and the Street has yet to take notice of the upside that exists over the next few years.
Today's price represents a very attractive entry point in our view. We are maintaining our Buy rating. We see $12 as fair-value based on $189.0 million in revenues in 2012 generating $1.68 in EPS. We apply an industry-like 25x multiple and discount back to present day at 30%.
The above story is the opinion of the author only and it does not reflect
iStockAnalyst opinion. Further, the author is not personally advising you
regarding the suitability of the story for your investment needs. In no event
iStockAnalyst will be liable for any loss or damage including without
limitation, indirect or consequential loss or damage, or any loss or damage
whatsoever arising from or arising out of, or in connection with the use of this
information. Please consult your investment advisor before making any investment
decision.
